The Latest Cardiac and Vascular News
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Amy Burroughs to its Board of Directors. […]
IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance1 today during its annual investor conference. Highlights of today’s conference include: Global market opportunity across 4 product groups projected to double to […]
NOT FOR RELEASE, EITHER DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative to people suffering from end-stage biventricular heart failure (the “Company”), […]
PARIS–(BUSINESS WIRE)–Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today discloses the total number of voting rights and shares as of November 30, 2022 (pursuant to Article L. 233-8 II of the […]
Medical information technology company receives investment of JPY550 million TOKYO–(BUSINESS WIRE)–SIMPLEX QUANTUM, Inc. has raised JPY550 million in a round of Series A funding. Simplex Holdings, Inc., along with the Technology Ventures No. 5 Investment Limited Partnership managed by ITOCHU Technology Ventures (ITV), and ITOCHU Corporation, invested the funds. This investment […]
TRiCares Successfully Closes Series C Financing, Raising €51m to Fund Further Development and Clinical Trials of Minimally Invasive Treatment for Tricuspid Regurgitation Paris, France and Munich, Germany, December 6, 2022 – TRiCares SAS (“TRiCares”) a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, is pleased to announce today the second closing and completion of its Series C […]
Combined company has full range of capabilities required to advance bold science for rare diseases in immunology and cardiopulmonology CARY, N.C., Dec. 06, 2022 (GLOBE NEWSWIRE) — Enzyvant Therapeutics, Inc. and Altavant Sciences, Inc., both wholly owned subsidiaries of Sumitovant Biopharma Ltd., today announced a merger to form a biopharmaceutical […]
CHARLESTOWN, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for patients with neuromuscular and cardiac diseases, today announced the grant of inducement awards to its newly appointed President and Chief Executive Officer, Alexander (Bo) Cumbo; Chief Administrative […]
Cardiovascular clinical trial expert brings AI imaging experience to lead research efforts NEW YORK–(BUSINESS WIRE)–Cleerly, the company creating a new standard of care for heart disease, announced it has appointed Udo Hoffmann, MD, MPH, as chief scientific officer. In this role, Dr. Hoffmann will oversee Cleerly’s large-scale research efforts, including […]
PARIS–(BUSINESS WIRE)–LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), today announced the appointment of Mike Mathias as Vice President of Commercial Operations. Mr. Mathias has spent his 30-year career successfully leading sales organizations […]
